Molecular therapy of breast cancer: progress and future directions

	Molecular therapy of breast cancer: progress and future directions
	Lin, SX; Chen, J; Mazumdar, M; Poirier, D; Wang, C; Azzi, A; Zhou, M
刊名	NATURE REVIEWS ENDOCRINOLOGY
	2010
卷号	6 期号:9 页码:485-493
通讯作者	Lin, SX (reprint author), CHU Laval, Lab Mol Endocrinol & Oncol, Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.,sheng-xiang.lin@crchul.ulaval.ca
英文摘要	Breast cancer is a major cause of death in Western women, with a 10% lifetime risk of the disease. Most breast cancers are estrogen-dependent. Molecular therapies for breast cancer have developed rapidly in the past few decades and future treatment strategies are being investigated. The selective estrogen receptor (ER) modulator tamoxifen, which until now has served as a standard therapy, functions not only as an estrogen antagonist but also as an estrogen agonist in terms of bone maintenance. Aromatase inhibitors have performed well in international trials and have become a new standard therapy for estrogen-dependent breast cancer. The systematic study of estrogen activation pathways suggests that the enzymes steroid sulfatase and 17 beta-hydroxysteroid dehydrogenase type 1, which both have pivotal roles in estrogen biosynthesis, are promising targets; the results of a phase I trial of steroid sulfatase inhibitors are encouraging. The activity of the human epidermal growth factor receptor (HER) pathway correlates negatively with that of the ER. HER2 is overexpressed in 22% of all breast cancers. In the decade since HER2 began being targeted, the monoclonal antibody trastuzumab has been used as well as pertuzumab and HER2 vaccines. Among the estrogen-independent breast cancers, the basal-like subtype has low survival, and therapeutic improvement is a priority. Crosstalk between ER and HER2 signaling pathways means that combinatory therapies may hold the key to enhancement of treatment responses. Other molecular therapies involving functional genomics and RNA interference studies also hold promise.
学科主题	Endocrinology & Metabolism
类目[WOS]	Endocrinology & Metabolism
关键词[WOS]	STEROID SULFATASE INHIBITORS ; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE-1 ; AROMATASE INHIBITORS ; POSTMENOPAUSAL WOMEN ; ADJUVANT TREATMENT ; ENDOCRINE THERAPY ; RANDOMIZED-TRIAL ; HORMONE-RECEPTOR ; CELL-PROLIFERATION ; ESTROGEN SYNTHESIS
收录类别	SCI
语种	英语
WOS记录号	WOS:000281126900007
内容类型	期刊论文
版本	出版稿
源URL	[http://202.127.25.143/handle/331003/1051]
专题	上海生化细胞研究所_上海生科院生化细胞研究所
推荐引用方式 GB/T 7714	Lin, SX,Chen, J,Mazumdar, M,et al. Molecular therapy of breast cancer: progress and future directions[J]. NATURE REVIEWS ENDOCRINOLOGY,2010,6(9):485-493.
APA	Lin, SX.,Chen, J.,Mazumdar, M.,Poirier, D.,Wang, C.,...&Zhou, M.(2010).Molecular therapy of breast cancer: progress and future directions.NATURE REVIEWS ENDOCRINOLOGY,6(9),485-493.
MLA	Lin, SX,et al."Molecular therapy of breast cancer: progress and future directions".NATURE REVIEWS ENDOCRINOLOGY 6.9(2010):485-493.